- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01058655
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Primary Objective
Phase I
- To determine the safety, tolerability, and maximally tolerated dose (MTD) of everolimus and tivozanib administered in combination to patients with advanced gastrointestinal tumors.
Phase II
- At the MTD, to assess progression-free survival associated with everolimus and tivozanib in patients with refractory, metastatic colorectal cancer.
Secondary Objectives
Phase II
- To assess tumor response rate.
- To assess overall survival.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Beth Israel Deaconess Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
For the Phase I component:
Inclusion Criteria:
- 18 years of age or older
- Histologic confirmation of a gastrointestinal malignancy, limited to cancer of the esophagus, stomach, small bowel, liver, biliary tract, gallbladder, pancreas, large bowel, appendix, rectum and anus.
- Locally advanced or metastatic disease
- Disease that: a) has recurred or progressed following standard therapy, b) for which no standard therapy currently exists, or c) for which the subject is not a candidate for or unwilling to undergo standard therapy. There is no limit to the number of prior regimens received by the patient.
- ECOG Performance Status of 0, 1 or 2
- Life expectancy of at least 12 weeks
- Adequate organ function as outlined in the protocol
- At least 4 weeks is required from : a) previous regimen of chemotherapy, b) immunotherapy or biological therapy, c) other investigational agents, and d) radiotherapy.
- At least 4 weeks is required from treatment of bevacizumab
- At least 4 weeks is required from prior systemic hormonal therapy or treatment with strong CYP3A4 inducers or inhibitors
- If female and of child bearing potential, documentation of negative pregnancy test prior to enrollment.
Exclusion Criteria:
- Prior therapy with inhibitors of mTOR or VEGFR (prior treatment with bevacizumab is allowed).
- Clinically apparent CNS metastases or carcinomatous meningitis
- Clinically significant cardiovascular disease
- Major surgery within 4 weeks of the start of study treatment or patients who have not recovered from the side effects of any major surgery.
- Active bleeding diathesis or history of Grade 2 or greater clinically significant bleeding within 3 months of enrollment
- Active infection requiring antibiotics
- Participants with a known positive history of chronic Hepatitis B viral infection or known positive HBV-DNA test are excluded.
- History of interstitial pneumonitis or severely impaired lung function defined as 88% or less O2 saturation at rest in room air
- Immunocompromise or chronic use of immunosuppressant medications
- Uncontrolled serious medical or psychiatric illness
- Subjects with non-healing wounds, active peptic ulcers, or unhealed bone fractures
- Significant proteinuria, defined as urine dipstick protein of 3+ or greater
- Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past 3 years or any currently active malignancy
- Elevated fasting levels of the following: serum cholesterol, serum triglycerides, and serum glucose
- Patients who are pregnant or lactating
- Malabsorption, uncontrolled vomiting or diarrhea, or any disease significantly affecting gastrointestinal function that could interfere with absorption of study drugs
- Inability to swallow pills
For the phase II component, only patients with metastatic colorectal cancer will be enrolled.
For the Phase II component:
Inclusion Criteria (Phase II):
- 18 years of age or older
- Histologic confirmation of colorectal cancer
- Stage IV disease
- At least one site of disease measurable by RECIST criteria
- Receipt of or intolerance to a fluoropyrimidine (fluorouracil or capecitabine), irinotecan, oxaliplatin, bevacizumab, and a monoclonal antibody to epidermal growth factor receptor (cetuximab or panitumumab). If a patient's tumor was K-RAS mutation positive, then previous treatment with cetuximab or panitumumab is not required.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Life expectancy of at least 12 weeks
- Adequate organ function as outlined in the protocol
- At least 3 weeks is required from: (a) previous regimen of chemotherapy, (b)immunotherapy or biological therapy, (c) other investigational agents, and (d) radiotherapy. Of note, concomitant radiotherapy is NOT allowed, while a patient is on protocol.
- At least 3 weeks is required from prior treatment with bevacizumab
- At least 3 weeks is required since prior systemic hormonal therapy or treatment with strong CYP3A4 inducers or inhibitors.
- Negative pregnancy test for women of child bearing potential
Exclusion Criteria (Phase II):
- Prior therapy with inhibitors of mTOR or VEGFR (prior treatment with bevacizumab is allowed)
- Clinically apparent CNS metastases or carcinomatous meningitis, as determined by physical examination and imaging studies
- Clinically significant cardiovascular disease, defined as follows:
(A)Symptomatic congestive heart failure, (B)Symptomatic coronary artery disease or myocardial infarction within 3 months of enrollment, (C)Cardiac arrhythmias not controlled with medication, (D)Deep venous thrombosis or pulmonary embolus within the last 6 months, (E) Cerebrovascular accident within the last 12 months, (F)Poorly controlled hypertension, defined as systolic pressure > 150 mmHg or diastolic pressure > 100 mmHg documented on 2 consecutive measurements taken at least 24 hours apart, (G)Symptomatic peripheral vascular disease, defined as claudication on walking ≤
1 block
- Major surgery within 4 weeks of the start of study treatment or patients who have not recovered from the side effects of any major surgery. Major surgery defined as those surgeries that require general anesthesia
- Active bleeding diathesis or history of grade 2 or higher clinically significant bleeding (hemoptysis, hematemesis, hematochezia, or melena) within 3 months of enrollment
- Active infection requiring antibiotics
- Participants with a known positive history of chronic Hepatitis B viral infection or known positive HBV-DNA test are excluded.
- History of interstitial pneumonitis or severely impaired lung function defined as less than or equal to 88% O2 saturation at rest in room air.
- Immunocompromise or chronic use of immunosuppressant medications (prednisone ≤ 10 mg daily or the equivalent of a comparable steroid is allowed, if deemed necessary by a study investigator)
- Uncontrolled serious medical or psychiatric illness
- Subjects with non-healing wounds, active peptic ulcers, or unhealed bone fractures
- Significant proteinuria, defined as urine dipstick protein 3+ or greater
- Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past 3 years or any currently active malignancy.
- Elevated fasting levels of the following: serum cholesterol, serum triglycerides, and serum glucose.
- Patients who are pregnant or lactating
- Malabsorption, uncontrolled vomiting or diarrhea, or any disease significantly affecting gastrointestinal function that could interfere with absorption of study drugs
- Inability to swallow pills
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg
Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle.
Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
|
Inne nazwy:
Inne nazwy:
|
Eksperymentalny: Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg
Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle.
Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
|
Inne nazwy:
Inne nazwy:
|
Eksperymentalny: Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg
Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle.
Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
|
Inne nazwy:
Inne nazwy:
|
Eksperymentalny: Phase II: Everolimus 10 mg + Tivozanib 1 mg
Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle.
Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
|
Inne nazwy:
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Everolimus Maximum Tolerated Dose (MTD) [Phase I]
Ramy czasowe: Patients were assessed continuously for toxicity while on study. The observation period for MTD evaluation was the first 28 days (cycle 1) of treatment.
|
The everolimus MTD in combination with tivozanib is determined by the number of patients who experience a dose limiting toxicity (DLT).
See subsequent primary outcome measure for the DLT definition.
The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT.
If no DLTs are observed, the MTD is not reached.
|
Patients were assessed continuously for toxicity while on study. The observation period for MTD evaluation was the first 28 days (cycle 1) of treatment.
|
Tivozanib Maximum Tolerated Dose (MTD) [Phase I]
Ramy czasowe: Patients were assessed continuously for toxicity while on study. The observation period for MTD evaluation was the first 28 days (cycle 1) of treatment.
|
The tivozanib MTD in combination with everolimus is determined by the number of patients who experience a dose limiting toxicity (DLT).
See subsequent primary outcome measure for the DLT definition.
The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT.
If no DLTs are observed, the MTD is not reached.
|
Patients were assessed continuously for toxicity while on study. The observation period for MTD evaluation was the first 28 days (cycle 1) of treatment.
|
Dose Limiting Toxicity (DLT) [Phase I]
Ramy czasowe: Patients were assessed continuously for toxicity while on study. The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
A DLT was defined as a treatment-related (attribution possible, probable, definite) adverse event that meets any of the following criteria: Grade 3 (G3) or higher non-hematologic toxicity (excluding, nausea, vomiting, diarrhea, alopecia, hypertension, hypercholesterolemia, or hypertriglyceridemia); G3 diarrhea, nausea or vomiting lasting > 48 hours or leading to hospitalization, despite aggressive anti-diarrheal or anti-emetic medications; G4 diarrhea, despite aggressive anti-diarrheal medications; G4 vomiting, despite aggressive anti-emetic medications; G3 hypertension, for which blood pressure cannot be reduced to <150/100 with anti-hypertensive therapies; G4 hypertension or severe hypertension, as defined by systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg; G4 hypercholesterolemia or hypertriglyceridemia lasting > 7 days, despite appropriate use of anti-hyperlipidemic medications; G4 hematologic toxicity lasting for >5 days, including leukopenia, neutropen
|
Patients were assessed continuously for toxicity while on study. The observation period for DLT evaluation was the first 28 days (cycle 1) of treatment.
|
Progression-Free Survival (PFS) [Phase II]
Ramy czasowe: Disease was assessed radiographically to document clinical progression every 2 cycles on treatment. Participants were followed for up to 16 months since study entry.
|
PFS based on the Kaplan-Meier method is defined as the time from study entry to the earliest documentation of disease progression (PD) or death.
Participants alive without evidence of PD were censored at the earliest date of last disease assessment.
Per RECIST 1.0 criteria: progressive disease (PD) is at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
PD for the evaluation of non-target lesions is the appearance of one or more new lesions and/or unequivocal progression of non-target lesions.
|
Disease was assessed radiographically to document clinical progression every 2 cycles on treatment. Participants were followed for up to 16 months since study entry.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Disease Control Rate (DCR) [Phase II]
Ramy czasowe: Disease was assessed every 2 cycles on treatment. Median treatment duration on this study cohort was 2 months (range 1-16).
|
Disease Control Rate is defined as the percentage of patients who achieve confirmed stable disease (SD) or better on treatment based on RECIST 1.0 criteria.
Per RECIST 1.0 for target lesions, complete response (CR) is disappearance of all target lesions and partial response (PR) is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD.
Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started.
SD is neither PR nor PD.
For non-target lesions, PD is the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
|
Disease was assessed every 2 cycles on treatment. Median treatment duration on this study cohort was 2 months (range 1-16).
|
Overall Survival (OS) [Phase II]
Ramy czasowe: Long-term follow-up for survival was not specified per protocol. Participants were followed for up to 20 months on this study.
|
OS based on the Kaplan-Meier method is defined as the time from study entry to death or date last known alive.
|
Long-term follow-up for survival was not specified per protocol. Participants were followed for up to 20 months on this study.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Brian Wolpin, MD, Dana-Farber Cancer Institute
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Nowotwory
- Nowotwory według lokalizacji
- Nowotwory Układu Pokarmowego
- Choroby przewodu pokarmowego
- Choroby okrężnicy
- Choroby jelit
- Nowotwory jelit
- Choroby odbytu
- Nowotwory jelita grubego
- Nowotwory przewodu pokarmowego
- Fizjologiczne skutki leków
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Ewerolimus
Inne numery identyfikacyjne badania
- 09-276
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak przewodu pokarmowego
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Aktywny, nie rekrutującyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterAstraZenecaZakończonyRak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Stopień kliniczny II, w którym pośredniczy HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Patologiczny etap I, w którym pośredniczy HPV (p16-dodatni) rak jamy... i inne warunkiStany Zjednoczone